Biotech Values

[rkrw]

Alphaeon--the Evolus partner in the US has a business plan that may not consider whether docs care where it came from. Their pitch is they have many physician owners of their stock, covering some percentage of prescribers in the US, so they believe once approved that makes it an easy switch to grab that market share. Seems very aggressive, like doc owned MRI centers of the past. But I would have my doubts a doc owning say $5,000 in stock, they're probably wildly underwater on would motivate them to push all their patients to switch, of course.

They tried to raise debt, offering investors a 2.5x guaranteed return over 18 months, plus interest. That speaks to their financial desperation at the time, less than 2 years ago.